A major new study in the UK has shown that combining whole-genome sequencing (WGS) and real-world clinical data at a national scale can help deliver tailored, personalised
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.